Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.45 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232994 | 0.86 | MAPK14 (0.55) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL7210193 | 0.81 | MAPK14 (0.49) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL16097154 | 0.79 | MAPT (0.43) | MAPK14 | |
| SCHEMBL3058808 | 0.78 | MAPK14 (0.65) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL7232371 | 0.76 | MAPK14 (0.55) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL23009753 | 0.73 | DPP4 (0.59) | MAPK14DPP4MAPK10MAPK13MAPK12 | |
| SCHEMBL7071770 | 0.72 | XDH (0.61) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL8502079 | 0.71 | SRC (0.45) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL8502076 | 0.71 | SRC (0.45) | MAPK14MAPK10SRCBRAFKDR | |
| SCHEMBL27527720 | 0.71 | HTR7 (0.43) | MAPK14SRCBRAFKDRMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | MAPK14 2062/4885DPP4 301/4885MAPK10 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.